 <h1>Premarin Intravenous Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>conjugated estrogens</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about conjugated estrogens. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Premarin Intravenous.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to conjugated estrogens: oral tablet</i></p><p>Other dosage forms:</p><ul><li>intravenous powder for solution</li></ul><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Endometrial Cancer, Cardiovascular Disorders, Breast Cancer and Probable DementiaEstrogen-Alone TherapyThere is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens.Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia.Women's Health Initiative estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis.The Women’s Health Initiative Memory Study estrogen-alone ancillary study of Women’s Health Initiative reported an increased risk of probable dementia in postmenopausal women 65 years of age and older.Estrogen Plus Progestin TherapyEstrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia.The Women’s Health Initiative estrogen plus progestin substudy reported increased risks of stroke, DVT, pulmonary embolism, and myocardial infarction.The Women’s Health Initiative estrogen plus progestin substudy reported increased risks of invasive breast cancer.The Women’s Health Initiative Memory Study estrogen plus progestin ancillary study of Women’s Health Initiative reported an increased risk of probable dementia in postmenopausal women 65 years of age and older.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, conjugated estrogens (the active ingredient contained in Premarin Intravenous) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking conjugated estrogens:</p><p>
<i>More common</i>
</p><ul>
<li>Heavy non-menstrual vaginal bleeding</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Body aches or pain</li>
<li>chills</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>ear congestion</li>
<li>fever</li>
<li>headache</li>
<li>loss of voice</li>
<li>nasal congestion</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain and tenderness</li>
<li>acid or sour stomach</li>
<li>anxiety</li>
<li>backache</li>
<li>belching</li>
<li>bloody stools</li>
<li>blurred vision</li>
<li>breast tenderness, enlargement, pain, or discharge</li>
<li>change in vaginal discharge</li>
<li>change in vision</li>
<li>changes in skin color</li>
<li>chest pain or discomfort</li>
<li>clay-colored stools</li>
<li>clear or bloody discharge from the nipple</li>
<li>confusion</li>
<li>constipation</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>difficulty with speaking</li>
<li>dimpling of the breast skin</li>
<li>dizziness or lightheadedness</li>
<li>double vision</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>full or bloated feeling or pressure in the stomach</li>
<li>headache, severe and throbbing</li>
<li>heartburn</li>
<li>hives</li>
<li>hoarseness</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>indigestion</li>
<li>inverted nipple</li>
<li>irritation</li>
<li>itching</li>
<li>joint pain, stiffness, or swelling</li>
<li>loss of appetite</li>
<li>lump in the breast or under the arm</li>
<li>migraine headache</li>
<li>nausea</li>
<li>pain or discomfort in the arms, jaw, back, or neck</li>
<li>pain or feeling of pressure in the pelvis</li>
<li>pain, redness, or swelling in the arm or leg</li>
<li>pain, tenderness, or swelling of the foot or leg</li>
<li>painful or tender cysts in the breasts</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>persistent crusting or scaling of the nipple</li>
<li>poor insight and judgment</li>
<li>problems with memory or speech</li>
<li>rash</li>
<li>rectal bleeding</li>
<li>redness of the skin</li>
<li>redness or swelling of the breast</li>
<li>shortness of breath</li>
<li>slow speech</li>
<li>sore on the skin of the breast that does not heal</li>
<li>stomach discomfort or upset</li>
<li>sudden shortness of breath or troubled breathing</li>
<li>sweating</li>
<li>swelling of the abdominal or stomach area</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>trouble recognizing objects</li>
<li>trouble thinking and planning</li>
<li>trouble walking</li>
<li>troubled breathing or swallowing</li>
<li>unpleasant breath odor</li>
<li>vaginal bleeding</li>
<li>vomiting</li>
<li>vomiting of blood</li>
<li>wheezing</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of conjugated estrogens may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>excess air or gas in the stomach or intestines</li>
<li>itching of the vagina or genital area</li>
<li>lack or loss of strength</li>
<li>pain during sexual intercourse</li>
<li>passing gas</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Increased clear or white vaginal discharge</li>
<li>leg cramps</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>cramps</li>
<li>decreased interest in sexual intercourse</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>heavy bleeding</li>
<li>hives or welts</li>
<li>inability to have or keep an erection</li>
<li>increased hair growth, especially on the face</li>
<li>increased in sexual ability, desire, drive, or performance</li>
<li>increased interest in sexual intercourse</li>
<li>irritability</li>
<li>itching of the vagina or outside genitals</li>
<li>joint or muscle pain</li>
<li>loss in sexual ability, desire, drive, or performance</li>
<li>loss of scalp hair</li>
<li>mental depression</li>
<li>mood changes</li>
<li>muscle stiffness</li>
<li>pain</li>
<li>pain during sexual intercourse</li>
<li>pain in the ankles or knees</li>
<li>painful, red lumps under the skin, mostly on the legs</li>
<li>patchy brown or dark brown discoloration of the skin</li>
<li>rash</li>
<li>red, irritated eyes</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>swelling of the breasts or breast soreness in both females and males</li>
<li>thick, white curd-like vaginal discharge without odor or with mild odor</li>
<li>unexpected or excess milk flow from the breasts</li>
<li>weight changes</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to conjugated estrogens: injectable powder for injection, oral tablet, vaginal cream</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, palpitation, vasodilation</p>
<p><b>Rare</b> (less than 0.1%): Stroke</p>
<p><b>Postmarketing reports</b>: Deep and superficial venous thrombosis, pulmonary embolism, thrombophlebitis, myocardial infarction, stroke<sup>[Ref]</sup></p><p>-HRT is associated with a 1.3 to 3-fold increased relative risk of developing VTE, i.e., deep vein thrombosis or pulmonary embolism.  This event is more likely to occur in the first year of using HRT.</p>
<p>-The use of estrogen-only and estrogen-progestin therapy is associated with an up to 1.5 fold increased relative risk of ischemic stroke.</p>
<p>-The risk of hemorrhagic stroke is not increased during use of HRT.  This relative risk is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women who use HRT will increase with age.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne, alopecia, hirsutism, pruritus, rash, skin discoloration, sweating, fungal dermatitis</p>
<p><b>Postmarketing reports</b>: Chloasma or melasma (may persist when drug is discontinued), erythema multiforme, erythema nodosum, loss of scalp hair<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, diarrhea, dyspepsia, eructation, flatulence, nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): Bloating, abdominal pain</p>
<p><b>Postmarketing reports</b>: Vomiting, abdominal discomfort, abdominal distension<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Pelvic pain, breast disorder, breast enlargement, breast neoplasm, breast pain, cervix disorder, dysmenorrhea, endometrial disorder, endometrial hyperplasia, leukorrhea, metrorrhagia, urinary tract infection, uterine fibroids enlarged, uterine spasm, abnormal uterine bleeding (breakthrough bleeding/spotting), vaginal dryness, vaginal hemorrhage, vaginal moniliasis, vaginitis</p>
<p><b>Uncommon</b> (0.1% to 1%): Vaginal candidiasis, changes in menstrual flow, changes in cervical ectropion and secretion</p>
<p><b>Postmarketing reports</b>: Increases in seize of uterine leiomyomata, change in cervical secretion, ovarian cancer, endometrial cancer, breast tenderness, breast discharge, galactorrhea, fibrocystic breast changes, breast cancer, gynecomastia in males<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperlipidemia, weight gain, increased appetite</p>
<p><b>Very rare</b> (less than 0.01%): Hypocalcemia</p>
<p><b>Postmarketing reports</b>: Increase or decrease in weight, glucose intolerance, aggravation of porphyria, increased triglycerides<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, leg cramps, myalgia, muscle spasm<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, paresthesia, migraine, hypertonia, insomnia, nervousness</p>
<p><b>Very rare</b> (less than 0.01%): Exacerbation of chorea</p>
<p><b>Postmarketing reports</b>: Exacerbation of epilepsy, dementia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Accidental injury, asthenia, chills, flu syndrome, pain, edema, peripheral edema, generalized edema, moniliasis</p>
<p><b>Postmarketing reports</b>: Irritability<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, emotional liabilities, anxiety</p>
<p><b>Uncommon</b> (0.1% to 1%): Changes in libido, mood disturbances<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Chest pain, bronchitis, increased cough, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection</p>
<p><b>Postmarketing reports</b>: Exacerbation of asthma<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Gallbladder disease</p>
<p><b>Postmarketing reports</b>: Cholestatic jaundice, pancreatitis, enlargement of hepatic hemangiomas, ischemic colitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Rare</b> (less than 0.1%): Anaphylactic/anaphylactoid reactions including urticaria and angioedema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Intolerance to contact lenses, steepening of corneal curvature</p>
<p><b>Postmarketing reports</b>: Retinal vascular thrombosis<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Breast cancer: </p>
<p>-An up to 2-fold increased risk of having breast cancer diagnosed is reported in women taking combined estrogen-progestin therapy for more than 5 years.</p>
<p>-Any increased risk in users of estrogen-only therapy is substantially lower than that seen in users of estrogen-progestin combinations.  The level of risk is dependent on the duration of use.</p>
<p></p>
<p>Endometrial Cancer:</p>
<p>-Endometrial cancer risk is about 5 in every 1000 women with a uterus not using HRT.</p>
<p>-In women with a uterus, use of estrogen-only HRT is not recommended because it increases the risk of endometrial cancer.</p>
<p>-Depending on the duration of estrogen-only use and estrogen dose, the increase in risk of endometrial cancer varied from between 5 and 55 extra cases diagnosed in every 1000 women between the ages of 50 and 65.  </p>
<p>-Adding a progestin to estrogen-only therapy for at least 12 days per cycle can prevent this increased risk.  In the Million Women Study the use of five years of combined HRT did not increase risk of endometrial cancer.</p>
<p></p>
<p>Ovarian cancer:</p>
<p>-Long-term use of estrogen-only and combined estrogen-progestin HRT has been associated with a slightly increased risk of ovarian cancer.  In the Million Women Study 5 years of HRT resulted in 1 extra case per 2500 users.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Breast cancer, ovarian cancer, fibrocystic breast changes, growth potentiation of benign meningioma.  </p>
<p><b>Very rare</b> (less than 0.01%): Endometrial cancer, enlargement of hepatic hemangiomas<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995): 199-208</p><p id="ref_2">2. Collins P, Beale CM, Rosano GMC "Oestrogen as a calcium channel blocker." Eur Heart J 17 ( Suppl (1996): 27-31</p><p id="ref_3">3. Grady D, Wenger NK, Herrington D, et al. "Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen replacement study." Ann Intern Med 132 (2000): 689-96</p><p id="ref_4">4. Kamali P, Muller T, Lang U, Clapp JF "Cardiovascular responses of perimenopausal women to hormonal replacement therapy." Am J Obstet Gynecol 182 (2000): 17-22</p><p id="ref_5">5. Lindsay R,  Gallagher JC,  Kleerekoper M,  Pickar JH "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women." JAMA 287 (2002): 2668-76</p><p id="ref_6">6. Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978): 33-55</p><p id="ref_7">7. Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991): 1861-7</p><p id="ref_8">8. Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981): 528-31</p><p id="ref_9">9. Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995): 1-16</p><p id="ref_10">10. Herrington DM, Reboussin DM, Brosniham KB, et al. "Effects of estrogen replacement on the progression of coronary-artery atherosclerosis." N Engl J Med 343 (2000): 522-9</p><p id="ref_11">11. Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978): 1407-8</p><p id="ref_12">12. Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21</p><p id="ref_13">13. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_14">14. Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992): 1016-36</p><p id="ref_15">15. Miller J,  Chan BK,  Nelson HD "Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. preventive services task force." Ann Intern Med 136 (2002): 680-90</p><p id="ref_16">16. Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med 325 (1991): 756-62</p><p id="ref_17">17. "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_18">18. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_19">19. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, SchenckGustafsson K "A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease." J Hypertens 17 (1999): 1379-86</p><p id="ref_20">20. Gordeuk VR, Brittenham GM, Hughes M, Keating LJ, Opplt JJ "High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial." Am J Clin Nutr 46 (1987): 1029-34</p><p id="ref_21">21. Petitti DB "Hormone replacement therapy and heart disease prevention: experimentation trumps observation." JAMA 280 (1998): 650-2</p><p id="ref_22">22. "Product Information. Enjuvia (conjugated estrogens)." Barr Pharmaceuticals Inc, Pomona, NY. </p><p id="ref_23">23. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998): 605-13</p><p id="ref_24">24. Herrington DM "The HERS Trial results: paradigms lost?" Ann Intern Med 131 (1999): 463-6</p><p id="ref_25">25. Mendelsohn ME, Karas RH "The protective effects of estrogen on the cardiovascular system." N Engl J Med 340 (1999): 1801-11</p><p id="ref_26">26. Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997): 501-8</p><p id="ref_27">27. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980): 339-42</p><p id="ref_28">28. Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989): 1095-2100</p><p id="ref_29">29. Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71</p><p id="ref_30">30. Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974): 15-9</p><p id="ref_31">31. McClennan BL "Ischemic colitis secondary to Premarin: report of a case." Dis Colon Rectum 19 (1976): 618-20</p><p id="ref_32">32. Perusse R, Morency R "Oral pigmentation induced by Premarin." Cutis 48 (1991): 61-4</p><p id="ref_33">33. Wakatsuki A,  Okatani Y,  Ikenoue N,  Fukaya T "Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women." Circulation 106 (2002): 1771-6</p><p id="ref_34">34. Gambacciani M,  Ciaponi M,  Cappagli B,  Genazzani AR "Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women." Am J Obstet Gynecol 185 (2001): 1180-5</p><p id="ref_35">35. OrrWalker BJ, Horne AM, Evans MC, Grey AB, Murray MAF, McNeil AR, Reid IR "Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women." J Clin Endocrinol Metab 84 (1999): 1997-2001</p><p id="ref_36">36. Civitelli R,  Pilgram TK,  Dotson M, et al. "Alveolar and Postcranial Bone Density in Postmenopausal Women Receiving Hormone/Estrogen Replacement Therapy: A Randomized, Double-blind, Placebo-Controlled Trial." Arch Intern Med 162 (2002): 1409-15</p><p id="ref_37">37. Steiger MJ, Quinn NP "Hormone replacement therapy induced chorea." BMJ 302 (1991): 762</p><p id="ref_38">38. Jick SS, Walker AM, Jick H "Conjugated estrogens and fibrocystic breast disease." Am J Epidemiol 124 (1986): 746-51</p><p id="ref_39">39. Pastides H, Najjar MA, Kelsey JL "Estrogen replacement therapy and fibrocystic breast disease." Am J Prev Med 3 (1987): 282-6</p><p id="ref_40">40. Oppenheim G "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry 45 (1984): 34-5</p><p id="ref_41">41. Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977): 357-9</p><p id="ref_42">42. Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988): 115-9</p><p id="ref_43">43. Searcy CJ, Kushner M, Nell P, Beckmann CR "Anaphylactic reaction to intravenous conjugated estrogens." Clin Pharm 6 (1987): 74-6</p><p id="ref_44">44. Caucino JA, Armenaka M, Rosenstreich DL "Anaphylaxis associated with a change in premarin dye formulation." Ann Allergy 72 (1994): 33-5</p><p id="ref_45">45. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981): 497-506</p><p id="ref_46">46. Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982): 1017-25</p><p id="ref_47">47. Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986): 434-41</p><p id="ref_48">48. Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977): 570-1</p><p id="ref_49">49. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA "Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women." JAMA 274 (1995): 137-42</p><p id="ref_50">50. Ziel HK,  Finkle WD "Increased risk of endometrial carcinoma among users of conjugated estrogens." N Engl J Med 293 (1975): 1167-70</p><p id="ref_51">51. Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994): 1213-23</p><p id="ref_52">52. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991): 1386-95</p><p id="ref_53">53. Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979): 123</p><p id="ref_54">54. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991): 1375-85</p><p id="ref_55">55. Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977): 385-9</p><p id="ref_56">56. Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995): 1589-93</p><p id="ref_57">57. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K "Conjugated estrogens and breast cancer risk in women." J Natl Cancer Inst 67 (1981): 815-20</p><p id="ref_58">58. The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996): 370-5</p><p id="ref_59">59. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985): 969-72</p><p id="ref_60">60. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989): 147-51</p><p id="ref_61">61. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989): 293-7</p><p id="ref_62">62. Gapstur SM, Morrow M, Sellers TA "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women's health study." JAMA 281 (1999): 2091-7</p><p id="ref_63">63. Greendale GA, Reboussin BA, Sie A, et al. "Effects of estrogen and estrogen-progestin on mammographic parenchymal density." Ann Intern Med 130 (1999): 262-9</p><p id="ref_64">64. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979): 9-13</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Premarin Intravenous (conjugated estrogens)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>Drug class: estrogens</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Enjuvia, Cenestin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul>
<h3>Other Formulations</h3>
<ul class="more-resources-list more-resources-list-formulations">
<li>Premarin</li>
<li>Premarin Vaginal</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Abnormal Uterine Bleeding</li>
<li>Atrophic Urethritis</li>
<li>Atrophic Vaginitis</li>
<li>Breast Cancer, Palliative</li>
<li data-more-config-id="list-data-resources-conditions">... +6 more</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to conjugated estrogens: injectable powder for injection, oral tablet, vaginal cream</i></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, palpitation, vasodilation</p><p><b>Rare</b> (less than 0.1%): Stroke</p><p><b>Postmarketing reports</b>: Deep and superficial venous thrombosis, pulmonary embolism, thrombophlebitis, myocardial infarction, stroke<sup>[Ref]</sup></p><p>-HRT is associated with a 1.3 to 3-fold increased relative risk of developing VTE, i.e., deep vein thrombosis or pulmonary embolism.  This event is more likely to occur in the first year of using HRT.</p><p>-The use of estrogen-only and estrogen-progestin therapy is associated with an up to 1.5 fold increased relative risk of ischemic stroke.</p><p>-The risk of hemorrhagic stroke is not increased during use of HRT.  This relative risk is not dependent on age or on duration of use, but as the baseline risk is strongly age-dependent, the overall risk of stroke in women who use HRT will increase with age.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Acne, alopecia, hirsutism, pruritus, rash, skin discoloration, sweating, fungal dermatitis</p><p><b>Postmarketing reports</b>: Chloasma or melasma (may persist when drug is discontinued), erythema multiforme, erythema nodosum, loss of scalp hair<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Constipation, diarrhea, dyspepsia, eructation, flatulence, nausea</p><p><b>Uncommon</b> (0.1% to 1%): Bloating, abdominal pain</p><p><b>Postmarketing reports</b>: Vomiting, abdominal discomfort, abdominal distension<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Pelvic pain, breast disorder, breast enlargement, breast neoplasm, breast pain, cervix disorder, dysmenorrhea, endometrial disorder, endometrial hyperplasia, leukorrhea, metrorrhagia, urinary tract infection, uterine fibroids enlarged, uterine spasm, abnormal uterine bleeding (breakthrough bleeding/spotting), vaginal dryness, vaginal hemorrhage, vaginal moniliasis, vaginitis</p><p><b>Uncommon</b> (0.1% to 1%): Vaginal candidiasis, changes in menstrual flow, changes in cervical ectropion and secretion</p><p><b>Postmarketing reports</b>: Increases in seize of uterine leiomyomata, change in cervical secretion, ovarian cancer, endometrial cancer, breast tenderness, breast discharge, galactorrhea, fibrocystic breast changes, breast cancer, gynecomastia in males<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Hyperlipidemia, weight gain, increased appetite</p><p><b>Very rare</b> (less than 0.01%): Hypocalcemia</p><p><b>Postmarketing reports</b>: Increase or decrease in weight, glucose intolerance, aggravation of porphyria, increased triglycerides<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, leg cramps, myalgia, muscle spasm<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness, paresthesia, migraine, hypertonia, insomnia, nervousness</p><p><b>Very rare</b> (less than 0.01%): Exacerbation of chorea</p><p><b>Postmarketing reports</b>: Exacerbation of epilepsy, dementia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Accidental injury, asthenia, chills, flu syndrome, pain, edema, peripheral edema, generalized edema, moniliasis</p><p><b>Postmarketing reports</b>: Irritability<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression, emotional liabilities, anxiety</p><p><b>Uncommon</b> (0.1% to 1%): Changes in libido, mood disturbances<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Chest pain, bronchitis, increased cough, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection</p><p><b>Postmarketing reports</b>: Exacerbation of asthma<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Gallbladder disease</p><p><b>Postmarketing reports</b>: Cholestatic jaundice, pancreatitis, enlargement of hepatic hemangiomas, ischemic colitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Rare</b> (less than 0.1%): Anaphylactic/anaphylactoid reactions including urticaria and angioedema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Intolerance to contact lenses, steepening of corneal curvature</p><p><b>Postmarketing reports</b>: Retinal vascular thrombosis<sup>[Ref]</sup></p><h3>Oncologic</h3><p>Breast cancer: </p><p>-An up to 2-fold increased risk of having breast cancer diagnosed is reported in women taking combined estrogen-progestin therapy for more than 5 years.</p><p>-Any increased risk in users of estrogen-only therapy is substantially lower than that seen in users of estrogen-progestin combinations.  The level of risk is dependent on the duration of use.</p><p></p><p>Endometrial Cancer:</p><p>-Endometrial cancer risk is about 5 in every 1000 women with a uterus not using HRT.</p><p>-In women with a uterus, use of estrogen-only HRT is not recommended because it increases the risk of endometrial cancer.</p><p>-Depending on the duration of estrogen-only use and estrogen dose, the increase in risk of endometrial cancer varied from between 5 and 55 extra cases diagnosed in every 1000 women between the ages of 50 and 65.  </p><p>-Adding a progestin to estrogen-only therapy for at least 12 days per cycle can prevent this increased risk.  In the Million Women Study the use of five years of combined HRT did not increase risk of endometrial cancer.</p><p></p><p>Ovarian cancer:</p><p>-Long-term use of estrogen-only and combined estrogen-progestin HRT has been associated with a slightly increased risk of ovarian cancer.  In the Million Women Study 5 years of HRT resulted in 1 extra case per 2500 users.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Breast cancer, ovarian cancer, fibrocystic breast changes, growth potentiation of benign meningioma.  </p><p><b>Very rare</b> (less than 0.01%): Endometrial cancer, enlargement of hepatic hemangiomas<sup>[Ref]</sup></p><p id="ref_1">1. The Writing Group for the PEPI Trial "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial." JAMA 273 (1995): 199-208</p><p id="ref_2">2. Collins P, Beale CM, Rosano GMC "Oestrogen as a calcium channel blocker." Eur Heart J 17 ( Suppl (1996): 27-31</p><p id="ref_3">3. Grady D, Wenger NK, Herrington D, et al. "Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen replacement study." Ann Intern Med 132 (2000): 689-96</p><p id="ref_4">4. Kamali P, Muller T, Lang U, Clapp JF "Cardiovascular responses of perimenopausal women to hormonal replacement therapy." Am J Obstet Gynecol 182 (2000): 17-22</p><p id="ref_5">5. Lindsay R,  Gallagher JC,  Kleerekoper M,  Pickar JH "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women." JAMA 287 (2002): 2668-76</p><p id="ref_6">6. Crane MG, Harris JJ "Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium, and the renin-aldosterone system." Am J Med Sci 276 (1978): 33-55</p><p id="ref_7">7. Barrett-Connor E, Bush TL "Estrogen and coronary heart disease in women." JAMA 265 (1991): 1861-7</p><p id="ref_8">8. Wren BG, Routledge DA "Blood pressure changes: oestrogens in climacteric women." Med J Aust 2 (1981): 528-31</p><p id="ref_9">9. Schwartz J, Freeman R, Frishman W "Clinical pharmacology of estrogens: cardiovascular actions and cardioprotective benefits of replacement therapy in postmenopausal women." J Clin Pharmacol 35 (1995): 1-16</p><p id="ref_10">10. Herrington DM, Reboussin DM, Brosniham KB, et al. "Effects of estrogen replacement on the progression of coronary-artery atherosclerosis." N Engl J Med 343 (2000): 522-9</p><p id="ref_11">11. Jick H, Dinan B, Rothman KJ "Noncontraceptive estrogens and nonfatal myocardial infarction." JAMA 239 (1978): 1407-8</p><p id="ref_12">12. Crane MG, Harris JJ, Winsor W 3d "Hypertension, oral contraceptive agents, and conjugated estrogens." Ann Intern Med 74 (1971): 13-21</p><p id="ref_13">13. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_14">14. Grady D, Rubin SM, Petiti DB, et al. "Hormone therapy to prevent disease and prolong life in postmenopausal women." Ann Intern Med 117 (1992): 1016-36</p><p id="ref_15">15. Miller J,  Chan BK,  Nelson HD "Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. preventive services task force." Ann Intern Med 136 (2002): 680-90</p><p id="ref_16">16. Stampfer MJ, Colditz GA, Willett WC, et al. "Postmenopausal estrogen and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study." N Engl J Med 325 (1991): 756-62</p><p id="ref_17">17. "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories, Philadelphia, PA. </p><p id="ref_18">18. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_19">19. Pripp U, Hall G, Csemiczky G, Eksborg S, Landgren BM, SchenckGustafsson K "A randomized trial on effects of hormone therapy on ambulatory blood pressure and lipoprotein levels in women with coronary artery disease." J Hypertens 17 (1999): 1379-86</p><p id="ref_20">20. Gordeuk VR, Brittenham GM, Hughes M, Keating LJ, Opplt JJ "High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial." Am J Clin Nutr 46 (1987): 1029-34</p><p id="ref_21">21. Petitti DB "Hormone replacement therapy and heart disease prevention: experimentation trumps observation." JAMA 280 (1998): 650-2</p><p id="ref_22">22. "Product Information. Enjuvia (conjugated estrogens)." Barr Pharmaceuticals Inc, Pomona, NY. </p><p id="ref_23">23. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women." JAMA 280 (1998): 605-13</p><p id="ref_24">24. Herrington DM "The HERS Trial results: paradigms lost?" Ann Intern Med 131 (1999): 463-6</p><p id="ref_25">25. Mendelsohn ME, Karas RH "The protective effects of estrogen on the cardiovascular system." N Engl J Med 340 (1999): 1801-11</p><p id="ref_26">26. Sidney S, Petitti DB, Quesenberry CP "Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women." Ann Intern Med 127 (1997): 501-8</p><p id="ref_27">27. Rosenberg L, Slone D, Shapiro S, Kaufman D, Stolley PD, Miettinen OS "Noncontraceptive estrogens and myocardial infarction in young women." JAMA 244 (1980): 339-42</p><p id="ref_28">28. Barrett-Connor E, Wingard DL, Criqui MH "Postmenopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif, revisited." JAMA 261 (1989): 1095-2100</p><p id="ref_29">29. Belchetz PE "Hormonal treatment of postmenopausal women." N Engl J Med 330 (1994): 1062-71</p><p id="ref_30">30. Boston Collaborative Drug Surveilance Program "Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy." N Engl J Med 290 (1974): 15-9</p><p id="ref_31">31. McClennan BL "Ischemic colitis secondary to Premarin: report of a case." Dis Colon Rectum 19 (1976): 618-20</p><p id="ref_32">32. Perusse R, Morency R "Oral pigmentation induced by Premarin." Cutis 48 (1991): 61-4</p><p id="ref_33">33. Wakatsuki A,  Okatani Y,  Ikenoue N,  Fukaya T "Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women." Circulation 106 (2002): 1771-6</p><p id="ref_34">34. Gambacciani M,  Ciaponi M,  Cappagli B,  Genazzani AR "Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women." Am J Obstet Gynecol 185 (2001): 1180-5</p><p id="ref_35">35. OrrWalker BJ, Horne AM, Evans MC, Grey AB, Murray MAF, McNeil AR, Reid IR "Hormone replacement therapy causes a respiratory alkalosis in normal postmenopausal women." J Clin Endocrinol Metab 84 (1999): 1997-2001</p><p id="ref_36">36. Civitelli R,  Pilgram TK,  Dotson M, et al. "Alveolar and Postcranial Bone Density in Postmenopausal Women Receiving Hormone/Estrogen Replacement Therapy: A Randomized, Double-blind, Placebo-Controlled Trial." Arch Intern Med 162 (2002): 1409-15</p><p id="ref_37">37. Steiger MJ, Quinn NP "Hormone replacement therapy induced chorea." BMJ 302 (1991): 762</p><p id="ref_38">38. Jick SS, Walker AM, Jick H "Conjugated estrogens and fibrocystic breast disease." Am J Epidemiol 124 (1986): 746-51</p><p id="ref_39">39. Pastides H, Najjar MA, Kelsey JL "Estrogen replacement therapy and fibrocystic breast disease." Am J Prev Med 3 (1987): 282-6</p><p id="ref_40">40. Oppenheim G "A case of rapid mood cycling with estrogen: implications for therapy." J Clin Psychiatry 45 (1984): 34-5</p><p id="ref_41">41. Aldinger K, Ben-Menachem Y, Whalen G "Focal nodular hyperplasia of the liver associated with high-dosage estrogens." Arch Intern Med 137 (1977): 357-9</p><p id="ref_42">42. Conter RL, Longmire WP Jr "Recurrent hepatic hemangiomas. Possible association with estrogen therapy." Ann Surg 207 (1988): 115-9</p><p id="ref_43">43. Searcy CJ, Kushner M, Nell P, Beckmann CR "Anaphylactic reaction to intravenous conjugated estrogens." Clin Pharm 6 (1987): 74-6</p><p id="ref_44">44. Caucino JA, Armenaka M, Rosenstreich DL "Anaphylaxis associated with a change in premarin dye formulation." Ann Allergy 72 (1994): 33-5</p><p id="ref_45">45. Spengler RF, Clarke EA, Woolever CA, Newman AM, Osborn RW "Exogenous estrogens and endometrial cancer: a case-control study and assessment of potential biases." Am J Epidemiol 114 (1981): 497-506</p><p id="ref_46">46. Thomas DB, Persing JP, Hutchinson WB "Exogenous estrogens and other risk factors for breast cancer in women with benign breast diseases." J Natl Cancer Inst 69 (1982): 1017-25</p><p id="ref_47">47. Buring JE, Bain CJ, Ehrmann RL "Conjugated estrogen use and risk of endometrial cancer." Am J Epidemiol 124 (1986): 434-41</p><p id="ref_48">48. Gordon J, Reagan JW, Finkle WD, Ziel HK "Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate." N Engl J Med 297 (1977): 570-1</p><p id="ref_49">49. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA "Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women." JAMA 274 (1995): 137-42</p><p id="ref_50">50. Ziel HK,  Finkle WD "Increased risk of endometrial carcinoma among users of conjugated estrogens." N Engl J Med 293 (1975): 1167-70</p><p id="ref_51">51. Woodruff JD, Pickar JH "Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone." Am J Obstet Gynecol 170 (1994): 1213-23</p><p id="ref_52">52. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S "Breast cancer risk after estrogen replacement therapy: results from the Toronto Breast Cancer Study." Am J Epidemiol 134 (1991): 1386-95</p><p id="ref_53">53. Obrink A, Bunne G, Collen J, Tjernberg B "Endometrial cancer and exogenous estrogens." Acta Obstet Gynecol Scand 58 (1979): 123</p><p id="ref_54">54. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer ME, Zauber AG, Shapiro S "Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study." Am J Epidemiol 134 (1991): 1375-85</p><p id="ref_55">55. Gray LA Sr, Christopherson WM, Hoover RN "Estrogens and endometrial carcinoma." Obstet Gynecol 49 (1977): 385-9</p><p id="ref_56">56. Colditz GA, Hankinson SE, Hunter DJ, et al. "The use of estrogens and progestins and the risk of breast cancer in postmenopausal women." N Engl J Med 332 (1995): 1589-93</p><p id="ref_57">57. Hoover R, Glass A, Finkle WD, Azevedo D, Milne K "Conjugated estrogens and breast cancer risk in women." J Natl Cancer Inst 67 (1981): 815-20</p><p id="ref_58">58. The Writing Group for the PEPI Trial "Effects of hormone replacement therapy on endometrial histology in postmenopausal women." JAMA 275 (1996): 370-5</p><p id="ref_59">59. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, Lewis JL Jr, Knapp RC, Stolley PD, Schottenfeld D "Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens." N Engl J Med 313 (1985): 969-72</p><p id="ref_60">60. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C "Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study." BMJ 298 (1989): 147-51</p><p id="ref_61">61. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C "The risk of breast cancer after estrogen and estrogen-progestin replacement." N Engl J Med 321 (1989): 293-7</p><p id="ref_62">62. Gapstur SM, Morrow M, Sellers TA "Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa women's health study." JAMA 281 (1999): 2091-7</p><p id="ref_63">63. Greendale GA, Reboussin BA, Sie A, et al. "Effects of estrogen and estrogen-progestin on mammographic parenchymal density." Ann Intern Med 130 (1999): 262-9</p><p id="ref_64">64. Antunes CM, Strolley PD, Rosenshein NB, Davies JL, Tonascia JA, Brown C, Burnett L, Rutledge A, Pokempner M, Garcia R "Endometrial cancer and estrogen use. Report of a large case-control study." N Engl J Med 300 (1979): 9-13</p><h2>More about Premarin Intravenous (conjugated estrogens)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>Drug class: estrogens</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Other Formulations</h3><ul class="more-resources-list more-resources-list-formulations">
<li>Premarin</li>
<li>Premarin Vaginal</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Abnormal Uterine Bleeding</li>
<li>Atrophic Urethritis</li>
<li>Atrophic Vaginitis</li>
<li>Breast Cancer, Palliative</li>
<li data-more-config-id="list-data-resources-conditions">... +6 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>